Major salivary gland carcinomas: A 21-center cohort study of 892 patients with external validation of the UICC 9th edition n-classification.
An externally validated model predicts outcomes in rare salivary gland cancers, giving doctors an evidence-based framework for treatment decisions.
This large multicenter cohort with external validation establishes prognostic factors and staging validation for major salivary gland carcinomas, rare malignancies with limited prior evidence due to low incidence. The externally validated model provides a practical prognostic framework to guide treatment decisions across oncology centers.
What the study was
- Study design
- Multicenter cohort study with external validation (n=892, 21 centers)
- Population
- Major salivary gland carcinoma patients (21 international centers)
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Oral oncology
Why it surfaced
Largest externally validated cohort for rare salivary gland carcinomas; fills critical evidence gap for a malignancy lacking prospective trials, with actionable prognostic model.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.